Monday, November 30, 2009

Amgen Highlights Data to be Presented at ASH

THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/—Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for Nplate?? (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Additionally, Amgen will present the first Nplate study in a pediatric setting as well as in patients with myelodysplastic syndromes (MDS) at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition (Dec. 5 - 8, 2009).

Read the rest of this entry

Posted in Press Releases

Monday, November 23, 2009

Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards

THOUSAND OAKS, Calif., Nov. 23—Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London.

Read the rest of this entry

Posted in Press Releases

Monday, November 16, 2009

Amgen to Present at Lazard Capital Healthcare Conference

THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Thursday, November 12, 2009

Amgen to Present at 18th Annual Credit Suisse Healthcare Conference

THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) will participate in the 18th Annual Credit Suisse Healthcare Conference on Thursday, Nov. 12, 2009, at the Biltmore Hotel in Phoenix, Ariz., beginning at 9:30 a.m. Mountain Time. Robert A. Bradway, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Thursday, November 05, 2009

Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer

THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/—Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix (R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival.  Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.

Read the rest of this entry

Posted in Press Releases